10 Jun 2025 • In patients with ischemic stroke attributed to both atrial fibrillation (AF) and large-artery atherosclerosis, oral anticoagulant (OAC) monotherapy significantly outperformed antiplatelet therapy (APT) in reducing adverse outcomes.

OAC use was linked to a 59% reduction in composite cardiovascular events, death, or major bleeding (HR 0.41), and an 88% lower risk of death alone (HR 0.12) compared to APT.

These findings reinforce OAC monotherapy as the preferred strategy in this complex stroke subgroup.

Source: Frontiers | Read Full Story